Tactive Advisors LLC Takes Position in 10x Genomics $TXG

Tactive Advisors LLC purchased a new position in 10x Genomics (NASDAQ:TXG) during the second quarter, Holdings Channel reports. The fund purchased 12,495 shares of the company’s stock, valued at approximately $479,000.

Other large investors have also added to or reduced their stakes in the company. Intech Investment Management LLC boosted its stake in 10x Genomics by 1.4% in the fourth quarter. Intech Investment Management LLC now owns 40,047 shares of the company’s stock valued at $653,000 after acquiring an additional 567 shares during the last quarter. Certuity LLC increased its stake in shares of 10x Genomics by 4.7% during the 4th quarter. Certuity LLC now owns 20,204 shares of the company’s stock worth $330,000 after purchasing an additional 904 shares during the last quarter. Stratos Wealth Partners LTD. increased its stake in shares of 10x Genomics by 7.3% during the 4th quarter. Stratos Wealth Partners LTD. now owns 14,052 shares of the company’s stock worth $229,000 after purchasing an additional 950 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of 10x Genomics by 16.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 7,186 shares of the company’s stock worth $153,000 after purchasing an additional 1,012 shares during the period. Finally, Kera Capital Partners Inc. raised its holdings in shares of 10x Genomics by 2.3% in the 1st quarter. Kera Capital Partners Inc. now owns 48,937 shares of the company’s stock worth $1,039,000 after purchasing an additional 1,108 shares during the period. Hedge funds and other institutional investors own 84.68% of the company’s stock.

10x Genomics Stock Performance

Shares of NASDAQ:TXG opened at $52.03 on Monday. The firm has a fifty day moving average of $39.28 and a 200 day moving average of $27.67. 10x Genomics has a 52-week low of $11.16 and a 52-week high of $52.22. The firm has a market capitalization of $6.61 billion, a PE ratio of -88.18 and a beta of 2.03.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.10. The firm had revenue of $151.04 million for the quarter, compared to analyst estimates of $146.67 million. 10x Genomics had a negative return on equity of 9.41% and a negative net margin of 12.18%.The company’s revenue was down 12.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.28 EPS. On average, sell-side analysts forecast that 10x Genomics will post -0.78 EPS for the current fiscal year.

Trending Headlines about 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Q2 results exceeded expectations: 10x Genomics reported an adjusted loss of $0.14 per share, better than the $0.23–$0.24 consensus loss, while revenue of $151.0 million topped estimates near $146.7 million. 10x Genomics Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: 2026 outlook was raised: Management now expects full-year revenue of $610 million to $630 million, with the midpoint slightly above Wall Street’s approximately $613.8 million forecast. The guidance increase signals confidence in demand and supports the stock’s positive reaction. 10x Genomics Raises 2026 Revenue Outlook
• Positive Sentiment: Gross margin improved: Expansion in gross margin adds to the earnings beat and suggests improving operating leverage, even though the company remains unprofitable.
• Neutral Sentiment: Atera shipments remained around 40 units: The company maintained this shipment level while raising its outlook, but investors may be watching for further acceleration in instrument placements. 10x Genomics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Sales and earnings remain pressured year over year: Revenue declined 12.7% from the prior-year quarter, and the company posted a loss versus prior-year EPS of $0.28. Continued losses and an expected full-year loss remain risks despite the improved outlook.

Analyst Upgrades and Downgrades

TXG has been the topic of several research reports. Zacks Research lowered 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Morgan Stanley boosted their price objective on 10x Genomics from $37.00 to $40.00 and gave the company an “equal weight” rating in a research note on Friday. Barclays increased their target price on shares of 10x Genomics from $30.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. JPMorgan Chase & Co. lifted their target price on shares of 10x Genomics from $17.00 to $20.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of 10x Genomics in a research note on Wednesday, June 24th. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, 10x Genomics presently has a consensus rating of “Hold” and an average price target of $34.83.

Insider Transactions at 10x Genomics

In other news, CFO Adam Taich sold 15,098 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $24.44, for a total value of $368,995.12. Following the completion of the sale, the chief financial officer directly owned 379,898 shares in the company, valued at approximately $9,284,707.12. The trade was a 3.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Benjamin J. Hindson sold 11,595 shares of the company’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $24.44, for a total transaction of $283,381.80. Following the completion of the sale, the insider directly owned 502,000 shares of the company’s stock, valued at $12,268,880. This trade represents a 2.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 91,309 shares of company stock worth $2,581,357 in the last three months. Corporate insiders own 8.84% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.